Table 2.

Changes in Bone Parameters over Study Period

Median (Q1, Q3) or no. (%)	HIV+ Combined (N=81)	P°	Supplementation Dose* (N=51)	P°	Standard Dose** (N=30)	P°	P†
25(OH)D, ng/mL	+18.0 (+8.8, +32.0)	<0.001	+42 (+33, +53)	<0.001	+31 (+22, +37)	<0.001	0.001
PTH, pg/mL	+6.7 (−18.0, +19.9)	0.30	+7.2 (−11.5, +15.9)	0.37	+1.8 (−23.1, +25.0)	0.60	0.91
% Δ in spine BMD	+2.4 (−0.08, +6.0)	<0.001	+2.8 (−0.04, +7.2)	<0.001	+1.4 (−0.16, +3.5)	0.87	0.29
% Δ in hip BMD	+0.87 (−1.6, +2.8)	0.08	+0.93 (−0.7, +3.2)	0.03	+0.61 (−2.6, +2.1)	0.002	0.37
Spine z-score	+0.1 (−0.1, +0.4)	0.007	+0.2 (−0.1, +0.4)	0.005	0.0 (−0.6, +0.3)	0.51	0.15
Hip z-score	0.0 (−0.2, +0.2)	0.44	0.0 (−0.2, +0.1)	0.56	−0.05 (−0.2, +0.2)	0.50	0.68
Osteocalcin, ng/mL	−2.9 (−9.2, +3.8)	0.03	−3.3 (−10.1, +3.5)	0.046	−2.2 (−8.0, +4.42)	0.34	0.67
B-CrossLaps, ng/mL	−0.09 (−0.24, +0.09)	0.03	−0.09 (−0.25, +0.06)	0.01	−0.07 (−0.19, +0.15)	0.74	0.23
P1NP, ng/mL‡	−6.7 (−21.0, +4.6)	0.003	−12.8 (−25.4, 0.0)	0.001	0.0 (−13.1, +12.1)	0.61	0.06

^*Supplementation dose = 60,000 IU/month (moderate dose) or 120,000 IU/month (high dose);

^**Standard dose = 18,000 IU/month (control dose);

^°P value for changes within group;

^†P value for differences in changes between the two dosing arms;

^‡The upper limit of detection for P1NP was 300 ng/mL. At the 12-month time point, 11.8% and 23.3% of subjects in the supplementation and standard arms, respectively, had unmeasurable values above the upper limit and were assigned a value of 300 ng/mL for the purpose of calculation of change from baseline. Bold-faced P values indicate those <0.05.

Q, quartile; 25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; P1NP, procollagen type 1 amino-terminal propeptide